Industry
Biotechnology
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b clinical trials in systemic lupus erythematosus and lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of KZR-261; and KZR-TBD for the treatment of oncology and immunology. The company was incorporated in 2015 and is based in South San Francisco, California.
Loading...
Open
6.79
Mkt cap
49M
Volume
29K
High
6.96
P/E Ratio
-0.51
52-wk high
11.40
Low
6.72
Div yield
N/A
52-wk low
5.20
Portfolio Pulse from
November 05, 2024 | 4:15 pm
Portfolio Pulse from Benzinga Newsdesk
October 30, 2024 | 12:55 pm
Portfolio Pulse from Benzinga Newsdesk
October 29, 2024 | 11:50 pm
Portfolio Pulse from Benzinga Insights
October 29, 2024 | 8:15 pm
Portfolio Pulse from Benzinga Newsdesk
October 28, 2024 | 12:38 pm
Portfolio Pulse from Benzinga Newsdesk
October 18, 2024 | 11:09 am
Portfolio Pulse from Vandana Singh
October 17, 2024 | 5:37 pm
Portfolio Pulse from Benzinga Newsdesk
October 17, 2024 | 12:45 pm
Portfolio Pulse from Benzinga Newsdesk
October 17, 2024 | 12:32 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.